The study of the immunodetection of metalloproteases in PC-3 tumours revealed that the combined treatment caused a decrease in MMP-2 and MMP-9; in the latter case, this was similar, although somewhat weaker, to that obtained after treatment with MIA-690. The gene discussed is MMP2; the disease is neoplasm.